Enlivex (ENLV) Total Liabilities (2013 - 2025)
Enlivex (ENLV) posted quarterly Total Liabilities of $392.0 million for Q4 2025, up 9466.86% year-over-year from $4.1 million in Q4 2024, and up 11240.76% quarter-over-quarter from $3.5 million in Q3 2025.
Enlivex (ENLV) Total Liabilities (2013 - 2025) Analysis & Trends
Enlivex's Total Liabilities history runs 13 years deep, the most recent figure standing at $392.0 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 9466.86% year-over-year to $392.0 million; the TTM figure through Dec 2025 stood at $392.0 million (up 9466.86% YoY), while the FY2025 annual figure was $392.0 million, up 9466.86% from the prior year.
- Total Liabilities for Q4 2025 stood at $392.0 million, up from $3.5 million in the prior quarter.
- The five-year high for Total Liabilities was $392.0 million in Q4 2025, with the low at $3.2 million in Q3 2024.
- The 5-year median for Total Liabilities is $7.5 million (2023), against an average of $26.0 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities slumped 61.58% in 2024, then surged 9466.86% in 2025.
- Enlivex's Total Liabilities stood at $10.1 million in 2021, then gained by 6.87% to $10.8 million in 2022, then sank by 37.53% to $6.7 million in 2023, then plunged by 39.26% to $4.1 million in 2024, then soared by 9466.86% to $392.0 million in 2025.
- Business Quant data shows ENLV's Total Liabilities at $392.0 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 392.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 392.05 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 3.54 Mn |
| Mar 31, 2025 | 3.41 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Dec 31, 2023 | 6.75 Mn |
| Sep 30, 2023 | 8.16 Mn |
| Jun 30, 2023 | 8.69 Mn |
| Mar 31, 2023 | 9.45 Mn |
| Dec 31, 2022 | 10.80 Mn |
| Sep 30, 2022 | 9.14 Mn |
| Jun 30, 2022 | 8.86 Mn |
| Mar 31, 2022 | 10.97 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Sep 30, 2021 | 10.08 Mn |
| Jun 30, 2021 | 4.98 Mn |
| Mar 31, 2021 | 5.36 Mn |